Zacks Investment Research upgraded shares of Corindus Vascular Robotics Inc. (NYSEMKT:CVRS) from a sell rating to a hold rating in a research note released on Wednesday.

According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “

Shares of Corindus Vascular Robotics (NYSEMKT:CVRS) opened at 1.17 on Wednesday. The firm’s market cap is $139.16 million. The stock’s 50 day moving average is $1.29 and its 200 day moving average is $1.24. Corindus Vascular Robotics has a 12 month low of $0.73 and a 12 month high of $3.61.

Corindus Vascular Robotics (NYSEMKT:CVRS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Analysts forecast that Corindus Vascular Robotics will post ($0.25) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. increased its position in Corindus Vascular Robotics by 236.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 84,000 shares of the company’s stock valued at $121,000 after buying an additional 59,000 shares in the last quarter. California State Teachers Retirement System increased its stake in Corindus Vascular Robotics by 139.3% in the second quarter. California State Teachers Retirement System now owns 115,258 shares of the company’s stock worth $165,000 after buying an additional 67,091 shares in the last quarter. State Street Corp increased its stake in Corindus Vascular Robotics by 16.7% in the first quarter. State Street Corp now owns 230,500 shares of the company’s stock worth $226,000 after buying an additional 32,954 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Corindus Vascular Robotics by 44.4% in the second quarter. Bank of New York Mellon Corp now owns 164,570 shares of the company’s stock worth $235,000 after buying an additional 50,636 shares in the last quarter. Finally, BlackRock Investment Management LLC increased its stake in Corindus Vascular Robotics by 128.5% in the second quarter. BlackRock Investment Management LLC now owns 178,093 shares of the company’s stock worth $255,000 after buying an additional 100,170 shares in the last quarter.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures.

Receive News & Ratings for Corindus Vascular Robotics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.